Compare COHU & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | NVCR |
|---|---|---|
| Founded | 1947 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1994 | 2015 |
| Metric | COHU | NVCR |
|---|---|---|
| Price | $32.18 | $10.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $34.00 | $28.08 |
| AVG Volume (30 Days) | 517.7K | ★ 1.1M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | N/A | ★ N/A |
| Revenue | $452,956,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $14.38 | $7.72 |
| Revenue Next Year | $19.12 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.74 | 8.28 |
| 52 Week Low | $12.80 | $9.82 |
| 52 Week High | $34.96 | $20.05 |
| Indicator | COHU | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 39.56 |
| Support Level | $27.53 | N/A |
| Resistance Level | $34.96 | $13.59 |
| Average True Range (ATR) | 1.72 | 0.57 |
| MACD | 0.22 | -0.14 |
| Stochastic Oscillator | 86.75 | 19.73 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection).
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.